Cyclopharm (ASX:CYC) has achieved a milestone in its American commercial rollout, announcing a new multi-site agreement with Northwestern Memorial HealthCare, a premier academic health system based in Chicago.
The seven-site deal marks a critical "lighthouse win" for the company, establishing a firm presence in one of the most strategically vital healthcare markets in the United States.
Northwestern Memorial Hospital is currently ranked among the top 20 hospitals nationwide by U.S. News & World Report, lending immense clinical credibility to Cyclopharm’s proprietary Technegas technology.
The agreement specifies an immediate installation of Technegas at the flagship Northwestern Memorial Hospital, with a clear expansion pathway for up to six additional installations across the broader network over time.
Beyond the initial hardware placement, the partnership secures a stable recurring revenue model through the ongoing sale of consumables required for each patient procedure, alongside annual service and support fees.
By securing high-quality reference sites within leading Integrated Delivery Networks, Cyclopharm is executing its strategy to scale operations across the Midwest and beyond.
At the time of reporting, Cyclopharm's share price was $0.85.